Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study

Table 4 Administration schedule

Rounds	Route	WJ-MSC
Round 1	IT	1 × 106 cells/kg in 3 mL
	IV	1 × 106 cells/kg in 30 mL
	IM	1 × 106 cells/kg in 20 mL
Round 2 (week 1)	IT	1 × 106 cells/kg in 3 mL
	IV	1 × 106 cells/kg in 30 mL
	IM	1 × 106 cells/kg in 20 mL
Round 3 (week 4)	IT	1 × 106 cells/kg in 3 mL
	IV	1 × 106 cells/kg in 30 mL
	IM	1 × 106 cells/kg in 20 mL
Round 4 (week 6)	IT	1 × 106 cells/kg in 3 mL
	IV	1 × 106 cells/kg in 30 mL
	IM	1 × 106 cells/kg in 20 mL

WJ-MSC: Wharton’s jelly derived mesenchymal stem cells; IT: Intrathecal; IM: Intramuscular; IV: Intravenous.